Collaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients.
FRANKLIN LAKES, N.J. , July 28, 2026 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has...
FRANKLIN LAKES, N.J. , July 22, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Michael (Mike) Garrison...
/BD%20Canada's%20head%20office%20building%20in%20Mississauga%2C%20On%2C%20Canada_%20%20By%20JHVEPhoto.jpeg)
Becton, Dickinson and Company will release its third-quarter earnings next month, and analysts anticipate a double-digit profit dip.
FRANKLIN LAKES, N.J. , July 9, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio...
Recognition from Vizient validates CentroVena One ™ as a breakthrough innovation designed to simplify central line insertion and enhance patient and clinician safety
/Resmed%20Inc_%20HQ%20photo-by%20JHVEPhoto%20via%20iStock.jpg)
While ResMed has underperformed relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
Although Becton, Dickinson and Company has underperformed its sector peers recently, analysts remain moderately optimistic about the stock’s prospects.
/Stryker%20Corp_%20HQ%20sign%20-by%20Sundry%20Photography%20via%20Shutterstock.jpg)
Despite Stryker’s underperformance relative to the S&P 500 Index over the past year, Wall Street analysts remain highly bullish about the stock’s prospects.
/Intuitive%20Surgical%20Inc%20laptop-%20by%20monticello%20via%20Shutterstock.jpg)
Despite recent underperformance relative to the healthcare sector, analysts remain fairly bullish on Intuitive Surgical's long-term fundamentals and growth potential.